Form 4: Teladoc Health Director Thomas McKinley Reports Routine Stock Transactions and New RSU Grant

Teladoc Health Director Thomas McKinley reported the conversion of 17,467 restricted stock units into common stock and the acquisition of 28,986 new restricted stock units.

Summary

• Thomas McKinley, a Director at Teladoc Health, Inc. (TDOC), reported changes in his beneficial ownership of company securities via a Form 4 filing.
• On May 21, 2025, 17,467 restricted stock units (RSUs) that were granted on May 23, 2024, vested and converted into an equal number of common shares of Teladoc Health.
• Following this conversion, McKinley's direct beneficial ownership of Teladoc Health common stock increased to 56,544 shares.
• On May 22, 2025, McKinley was granted an additional 28,986 restricted stock units.
• These newly granted RSUs are scheduled to vest in full on the earlier of May 22, 2026, or the day immediately preceding Teladoc's 2026 annual meeting of stockholders.

Sentiment

Score: 7

Explanation: The filing indicates routine insider compensation activities, including the vesting of existing equity and the grant of new equity, which generally aligns director interests with long-term company performance. There are no negative implications, but also no significant positive news beyond standard compensation.

Positives

• The vesting of 17,467 restricted stock units indicates a successful completion of a vesting period for a director, aligning their interests with shareholders.
• The grant of 28,986 new restricted stock units to Director Thomas McKinley demonstrates continued incentive and alignment of management with long-term company performance.

Future Outlook

NA

Industry Context

This Form 4 filing reflects routine insider compensation and ownership changes within Teladoc Health, a leading virtual healthcare provider. Such filings are common across all industries as part of executive and director compensation packages, aiming to align their interests with long-term shareholder value.

Stakeholder Impact

• Shareholders: The vesting and granting of restricted stock units to a director align the director's financial interests with the long-term performance of the company, potentially benefiting shareholders through improved governance and strategic decisions.
• Employees: While not directly impacting general employees, such compensation structures for leadership can reflect the company's overall approach to equity-based incentives.

Next Steps

• The newly granted 28,986 restricted stock units are expected to vest on the earlier of May 22, 2026, or the day immediately preceding Teladoc's 2026 annual meeting of stockholders.

Key Dates

Recommendation

Keywords

Teladoc Health, TDOC, Form 4, Insider Transaction, Restricted Stock Units, RSU, Stock Ownership, Director Compensation, Executive Compensation